Skip to content
OpenCapital
Get started

MiMedx Group MDXG Wound — Net Sales

Other product segments

Surgical
$36.37M+13.2%

Similar metrics at other companies

IAR
IARTWound Reconstruction — Total Revenues
$79.65M+6.5%
Enovis logo
ENOVSurgical — Net Sales
$317.13M+10.8%
Avanos Medical logo
AVNSSurgical pain and recovery — Net Sales
$21.8M-11.0%
Rayonier Advanced Materials logo
RYAMBiomaterials and other — Net Sales
$12.62M+12.2%
TFX
TFXSurgical — Net revenues
$106.79M+12.4%
Bioventus logo
BVSRestorative Therapies — Total Net Sales
$20.64M+4.6%

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's wound — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's wound — net sales?
MiMedx Group (MDXG) reported wound — net sales of $22.62M in Q1 2026.
How has MiMedx Group's wound — net sales changed year-over-year?
MiMedx Group's wound — net sales decreased by 59.7% year-over-year, from $56.07M to $22.62M.
What is the long-term trend for MiMedx Group's wound — net sales?
Over 3 years (2022 to 2025), MiMedx Group's wound — net sales has grown at a 16.2% compound annual growth rate (CAGR), from $175.97M to $276.33M.
What does wound — net sales mean?
This metric represents the total revenue generated from the sale of regenerative biomaterial products and bioimplants specifically designed for wound care applications. It reflects the market demand and commercial adoption of the company's amniotic tissue-based therapies within clinical settings. Tracking this figure helps investors assess the growth trajectory and competitive positioning of the company's primary therapeutic segment.